- Global Pharma News & Resources

Global Hemophilia Market to Reach $20.09 Billion by 2027 -

DUBLIN--(BUSINESS WIRE)--The "Hemophilia Market Research Report by Type, Treatment, Therapy, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to's offering.

The Global Hemophilia Market size was estimated at USD 10.52 billion in 2021, USD 11.69 billion in 2022, and is projected to grow at a CAGR 11.38% to reach USD 20.09 billion by 2027.

Market Segmentation & Coverage:

This research report categorizes the Hemophilia to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Type, the market was studied across Hemophilia A, Hemophilia B, and Hemophilia C.
  • Based on Treatment, the market was studied across On-demand and Prophylaxis.
  • Based on Therapy, the market was studied across Gene therapy, ITI therapy, and Replacement therapy.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Hemophilia Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Market Dynamics


  • Increasing prevalence of hemophilia across the world
  • Rising promotions and supportive initiatives by government to increase awareness on hemophilia
  • Emerging prevalence of hemophilia in new-borns


  • Concerns of adverse side effects and high cost of plasma pertinent products


  • Surge in technologically advanced products and innovations
  • Increasing adoption of prophylaxis treatment


  • Strict government regulations and reduced availability of product

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Hemophilia Market, by Type

7. Hemophilia Market, by Treatment

8. Hemophilia Market, by Therapy

9. Americas Hemophilia Market

10. Asia-Pacific Hemophilia Market

11. Europe, Middle East & Africa Hemophilia Market

12. Competitive Landscape

13. Company Usability Profiles

14. Appendix

Companies Mentioned

  • AmerisourceBergen Corporation
  • Baxter International, Inc.
  • Bayer AG
  • Biogen Idec, Inc.
  • BioMarin Pharmaceutical Inc
  • CSL Behring LLC
  • Diapharma Group
  • F. Hoffmann-La Roche Ltd.
  • FFF Enterprises, Inc.
  • Grifols SA
  • IQVIA Inc.
  • Kedrion S.p.A
  • Lineage Medical, Inc.
  • Novo Nordisk A/S
  • Octopharma AG
  • Pfizer, Inc.
  • Sanofi-Aventis SA
  • Takeda Pharmaceutical Company Limited

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 10-Aug-2022